KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Expenditures (2016 - 2026)

Regeneron Pharmaceuticals has reported Capital Expenditures over the past 18 years, most recently at $230.6 million for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 0.57% year-over-year to $230.6 million; the TTM value through Mar 2026 reached $899.7 million, up 5.69%, while the annual FY2025 figure was $898.4 million, 18.85% up from the prior year.
  • Capital Expenditures for Q1 2026 was $230.6 million at Regeneron Pharmaceuticals, down from $248.7 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $470.9 million in Q3 2025 and troughed at -$102.8 million in Q2 2023.
  • A 5-year average of $187.9 million and a median of $178.2 million in 2023 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 174.95% in 2023 and later tumbled 385.31% in 2025.
  • Year by year, Capital Expenditures stood at $152.2 million in 2022, then skyrocketed by 65.18% to $251.4 million in 2023, then fell by 20.6% to $199.6 million in 2024, then increased by 24.6% to $248.7 million in 2025, then dropped by 7.28% to $230.6 million in 2026.
  • Business Quant data shows Capital Expenditures for REGN at $230.6 million in Q1 2026, $248.7 million in Q4 2025, and $470.9 million in Q3 2025.